SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

NCT05375084 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Non Small Cell Lung Cancer
Solid Tumor

Interventions

DRUG: BBP-398 with nivolumab

Sponsor

Navire Pharma Inc., a BridgeBio company

Collaborators

[object Object]